Henlius and Intas receive Positive CHMP Opinion for HETRONIFLY …
WEBHenlius and Intas receive Positive CHMP Opinion for HETRONIFLY® (approved as HANSIZHUANG in China) in European markets as First-Line Treatment for adult patients with Extensive-Stage Small Cell ...
Hetronifly | European Medicines Agency (EMA)
WEB2 days ago · The active substance of Hetronifly is serplulimab, an antineoplastic monoclonal antibody (ATC code: L01FF12). By blocking the binding of PD-1 to PD-L1 and PD-L2, serplulimab potentiates T-cell responses, including anti-tumour responses. The benefits of Hetronifly in combination with carboplatin and etoposide have been shown in a study involving ...
Henlius and Intas receive Positive CHMP Opinion for HETRONIFLY ...
WEB1 day ago · News provided by. Accord Healthcare Sep 21, 2024, 02:00 ET. Share this article. Share to X. Share this article. Share to X ... - HETRONIFLY® (serplulimab) ...
Europe Recommends Lung Cancer Drug Hetronifly - Medscape
WEB1 day ago · September 20, 2024. 0. The European Medicines Agency (EMA) has recommended granting a marketing authorization for orphan medicine Hetronifly (serplulimab, Henlius Europe) to treat extensive stage ...
Henlius and Intas receive Positive CHMP Opinion for HETRONIFLY ...
WEB1 day ago · - HETRONIFLY® (serplulimab) is ... (Accord), one of Europe's fastest growing pharmaceutical companies, marks World Cancer Day 2024 today by taking part in news-style... More Releases From This Source
Henlius and Intas receive Positive CHMP Opinion for HETRONIFLY ...
WEB20 hours ago · – HETRONIFLY® (serplulimab) is expected to become the first anti-PD-1 monoclonal antibody available in Europe for first-line treatment of ES-SCLC ... RElated News. Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not …
Meeting highlights from the Committee for Medicinal Products for …
WEB3 days ago · The committee recommended granting a marketing authorisation for Hetronifly* (serplulimab), for the treatment of extensive-stage small cell lung cancer. Hympavzi* (marstacimab), received a positive opinion for the treatment of bleeding episodes in patients aged 12 years and older with severe haemophilia A or B, two types of a rare inherited ...
Henlius and Intas receive Positive CHMP Opinion for HETRONIFLY ...
WEB1 day ago · - HETRONIFLY® (serplulimab) ... News published on 21 september 2024 at 02:00 and distributed by: Le Lézard. About Contact us. Others sections. News wire. Follow us
Henlius e Intas reciben la opinión positiva del CHMP para HETRONIFLY …
WEB1 day ago · Henlius e Intas reciben la opinión positiva del CHMP para HETRONIFLY® (aprobado como HANSIZHUANG en China) en los mercados europeos como tratamiento de primera...
Updated efficacy and safety results from the phase 2 study of ...
WEBJun 2, 2022 · Secondary endpoints included ORR assessed by the investigators, duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. Results: As of July 10, 2021, 108 patients had received at least one dose of study treatment and were included in the safety set (SS).
- Some results have been removed